Could this startup have the cure for obesity? Meet Pep2Tango Therapeutics!
Versant Ventures has introduced Pep2Tango Therapeutics Inc., a biotechnology startup dedicated to pioneering next-generation therapies for weight loss. The company has secured significant, albeit undisclosed, ... Read More
Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges
Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More
Terns Pharmaceuticals faces market pressure following stock offering announcement
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing small-molecule product candidates for serious diseases such as oncology and obesity, has seen a significant decline in ... Read More
Quotient Sciences opens new $15m facility in Garnet Valley to boost drug development capabilities
Quotient Sciences, a UK-based drug development services provider, has inaugurated a new early phase formulation and manufacturing plant in Garnet Valley, Pennsylvania. The facility, spanning ... Read More
Taro Pharmaceutical ends licensing agreement with NovaBiotics over Novexatin failure
Taro Pharmaceutical Industries has terminated its licensing agreement with Scottish biotech company NovaBiotics concerning the Novexatin drug after disappointing clinical trial results. The decision follows ... Read More
Tolero Pharmaceuticals and AbbVie collaborate to advance AML treatment
Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie to explore the potential of combining their respective drugs, alvocidib and venetoclax, for the ... Read More
Charles River Laboratories to acquire MPI Research for $800m
In a strategic move to bolster its position in the pharmaceutical research sector, Charles River Laboratories International, Inc. has agreed to acquire Michigan-based non-clinical contract ... Read More
Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial
Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not meet the primary endpoint in the pivotal ... Read More